There 4 companies include: 1) BioAtla, a company that employs expertise in protein engineering to develop monoclonal antibodies with CAB profiles, 2) NextCure Inc., a bio-pharmaceutical company that focuses on the discovery and development of novel immuno-ongology therapeutic products, 3) Cortexyme, Inc., a company that seeks to develop therapeutics based on a new theory on the acuses of Alzheimer's disease, and 4) 4D Molecular Therapeutics, Inc., a bio-pharmaceutical company that designs, develops and commercializes transformative gene therapy.
"There is exciting scientific discovery happening both within Pfizer and beyond our walls, and we look forward to continuing to explore opportunities to bring our resources to emerging companies investigating in areas where we feel we could make a difference for patients," said Mikael Dolsten, M.D., Ph.D., President of Pfizer Worldwide Research and Development.
"The key for Pfizer is to be flexible in how we partner with different companies; we use a range of investment vehicles and collaboration models in R&D to help ensure we tap into the vast, rapidly-evolving ecosystem of healthcare innovation, looking to complement each other's capabilities so that together we can make a bigger impact."
Shares of Pfizer were trading higher by 0.45 percent at $31.13 early Monday morning.
See more from Benzinga
- Shares Of Mylan Slightly Higher Following Launch Of Generic Drug
- Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook
- Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.